Efficacy and Safety of Different Doses of Sacubitril Valsartan in the Treatment of Elderly Patients with Chronic Heart Failure
OBJECTIVE:To probe into the efficacy and safety of different doses of sacubitril valsartan in the treatment of elderly patients with chronic heart failure.METHODS:A total of 155 elderly patients with chronic heart failure admitted into the hospital from 2019 to 2021 were divided into the group A(n=35),group B(n=62)and group C(n=58)according to different dosage regimen.Group A was given 100 mg sacubitril valsartan twice a day(standard dose),group B received 50 mg sacubitril valsartan twice a day(lower dose),group C was treated with 25 mg sacubitril valsartan twice a day(lower dose).After continuous medication for 12 months,the total effective rate,improvement in cardiac structure and function,and incidence of adverse events were compared among three groups before and after treatment.RESULTS:After treatment,the total effective rates of the three groups were respectively 94.3%(33/35),90.3%(56/62)and 69.0%(40/58),with statistically significant differences(P<0.001).After treatment,the left ventricular ejection fraction in group A and group B was respectively(63.07±7.95)%and(55.52±11.31)%,which were significantly improved compared with those before treatment,and the improvement in group A was more significant than that in group B,while there was no significant improvement in group C.The left atrial diameter of patients in group A and group B was respectively(38.04±7.04)mm and(39.14±5.67)mm,which was significantly improved compared with those before treatment,while there was no significant improvement in group C.The left ventricular end-diastolic diameter in group A and group B was respectively(46.03±6.91)mm and(48.80±6.95)mm,which were significantly improved compared with those before treatment,while there was no significant improvement in group C.There was no significant difference in the incidence of adverse drug reactions among three groups(P>0.05).CONCLUSIONS:In the treatment of chronic heart failure in elderly patients,if multiple risk factors are considered and the standard dose cannot be tolerated,a reduced dose of 50 mg twice daily can be used,which may have the same clinical benefits.However,a reduced dose of 25 mg twice daily is not recommended.
万方数据
维普
